23andMe Stock

23andme.comHealthcare / Healthcare providers & servicesFounded: 2006Funding to Date: $876.61MM

23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.

Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for 23andMe.

Register Today

Team

Management Team

Steve Schoch
CFO
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Anne Wojcicki
CEO & Co-Founder
Fred Kohler
Vice President, People
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Mike Polcari
Vice President & Chief Architect

Board Members

Patrick Chung
Xfund
Roelof Botha
Sequoia Capital
Anne Wojcicki
23andMe
Neal Mohan
23andMe
Richard Scheller, Ph.D.
Self

Other companies like 23andMe in the Healthcare providers & services sector

Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$648.94MM
Sector
Last Round Est. Valuation
$1.39B
Sector
Last Round Est. Valuation
$5.7B
Sector
Last Round Est. Valuation
$37.8MM
Sector
Last Round Est. Valuation
$1.81B
Sector
Last Round Est. Valuation
$3.52B
Sector
Last Round Est. Valuation
$1.53B
Sector
Last Round Est. Valuation
$6.22B

News Highlights

23andMe Study Associates Gene Locus With COVID-19-Related Loss of Smell, Taste
A multi-ancestry genome-wide association study found that genetics likely contributes to the loss of smell or taste in COVID-19 patients.
People in the News: New Appointments at Roswell Biotechnologies, 23andMe, Akoya Biosciences, More
23andMe to Acquire Telemedicine Platform Company Lemonaid Health for $400M in Cash, Stock
Lemonaid Health, based in San Francisco, offers a platform that provides online access to a variety of telemedicine and pharmacy services.
Updated on: Sep 25, 2023